Apo A. Sezginer
Directeur Technique/Scientifique/R&D chez Invarium, Inc.
Profil
Apo A.
Sezginer is Chief Technology Officer of Invarium, Inc. Prior to joining Invarium he was Principal Scientist of Sensys Medical, Inc. and a Senior Scientist and Section Head of Schlumberger Ltd.
Dr. Sezginer received a Sc.D.
degree in Electrical Engineering from the Massachusetts Institute of Technology.
Postes actifs de Apo A. Sezginer
| Sociétés | Poste | Début |
|---|---|---|
Invarium, Inc.
 Invarium, Inc. Packaged SoftwareTechnology Services Invarium, Inc. provides patterning synthesis solutions. It provides best patterning solutions to customers engaged in design and manufacture of advanced integrated circuits to the semiconductor design and manufacturing industry. The company was founded in 2003 and is headquartered in San Jose, CA. | Directeur Technique/Scientifique/R&D | - |
Anciens postes connus de Apo A. Sezginer
| Sociétés | Poste | Fin |
|---|---|---|
| SCHLUMBERGER LIMITED | Directeur Technique/Scientifique/R&D | - |
Sensys Medical Ltd.
 Sensys Medical Ltd. Medical DistributorsDistribution Services Since 1995, Sensys Medical, Inc. (f.k.a. Instrumentation Metrics) has been diligently working on the development of a non-invasive blood glucose analyzer to assist those individuals with diabetes control their blood sugar levels. The Company intends to commercialize its Glucose Tracking System (GTSâ'¢), which will dramatically advance the practice of blood glucose monitoring and the science of diabetes disease management. Sensys Medical continues to advance the technologies necessary to successfully develop a device that is accurate, precise and simple to use in the hands of individuals. Sensys Medical scientists and engineers have furthered the understanding of non-invasive blood glucose measurement with advancements in the disciplines of tissue optics, multivariate statistics, optical engineering and analysis, detector materials, finite element analysis and applied computational fluid dynamics. These advances are continually tested in clinical trials and refined to ensure that individuals are capable of obtaining accurate non-invasive blood glucose measurements with minimal effort from the subject. As results from these trials become available, they will be shared through presentations and/or publications. | Directeur Technique/Scientifique/R&D | - |
Formation de Apo A. Sezginer
| Massachusetts Institute of Technology | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SCHLUMBERGER LIMITED | Industrial Services |
| Entreprise privées | 2 |
|---|---|
Invarium, Inc.
Invarium, Inc. Packaged SoftwareTechnology Services Invarium, Inc. provides patterning synthesis solutions. It provides best patterning solutions to customers engaged in design and manufacture of advanced integrated circuits to the semiconductor design and manufacturing industry. The company was founded in 2003 and is headquartered in San Jose, CA. | Technology Services |
Sensys Medical Ltd.
Sensys Medical Ltd. Medical DistributorsDistribution Services Since 1995, Sensys Medical, Inc. (f.k.a. Instrumentation Metrics) has been diligently working on the development of a non-invasive blood glucose analyzer to assist those individuals with diabetes control their blood sugar levels. The Company intends to commercialize its Glucose Tracking System (GTSâ'¢), which will dramatically advance the practice of blood glucose monitoring and the science of diabetes disease management. Sensys Medical continues to advance the technologies necessary to successfully develop a device that is accurate, precise and simple to use in the hands of individuals. Sensys Medical scientists and engineers have furthered the understanding of non-invasive blood glucose measurement with advancements in the disciplines of tissue optics, multivariate statistics, optical engineering and analysis, detector materials, finite element analysis and applied computational fluid dynamics. These advances are continually tested in clinical trials and refined to ensure that individuals are capable of obtaining accurate non-invasive blood glucose measurements with minimal effort from the subject. As results from these trials become available, they will be shared through presentations and/or publications. | Distribution Services |
